Zanidatamab + chemotherapy, with or without tislelizumab, may increase survival in metastatic or locally advanced gastroesophageal adenocarcinoma ...

Tukysa (tucatinib) may represent a new patient-friendly option as a first line maintenance treatment possibility for patients ...

In March 2025, The FDA awarded orphan drug designation to Nerlynx® (neratinib) for treating breast cancer patients with brain ...

First-line zanidatamab plus chemotherapy leads to ‘practice-changing’ PFS and overall survival gains in a phase 3 study of ...

Phase 1b study to evaluate combination of zongertinib and zanidatamab in HER2-positive breast cancer patients Ingelheim, Germany– 12 January, ...

Dr. Elena Elimova discusses how Ziihera-based therapy may change treatment for HER2+ locally advanced or metastatic ...

Forget about Herceptin. There’s a new HER2 agent that ought to be used in HER2-positive stomach cancer, and that’s Jazz ...

Positive results from Phase 3 HERIZON-GEA-01 results support Ziihera as the HER2-targeted agent-of-choice in HER2+ first-line ...

Patients should be selected for treatment with Enhertu in combination with pertuzumab based on confirmed HER2-positive status or HER2 gene amplification (IHC 3+ or ISH+).

DESTINY-Breast05 is a large phase 3 trial in women with HER2-positive early-stage breast cancer who had chemotherapy and ...

Investigator sought to compare treatment strategies that omit chemotherapy and/or include ribociblib against standard treatment for safety and efficacy.

Bio‑Sourcing and Zerion Pharma A/S today announce that their joint project to develop an oral formulation of Trastuzumab, the pioneer monoclonal antibody used to treat breast cancer, has been awarded ...